Publications 2022

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Henriksen BT, Andersson Y, Davies MN, Mathiesen L, Krogseth M, Andersen RD (2022)
Development and initial validation of MedHipPro-Q: a questionnaire assessing medication management of hip fracture patients in different care settings
BMC Health Serv Res, 22 (1), 240
DOI 10.1186/s12913-022-07524-2, PubMed 35193572

Publications 2021

Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers (Basel), 13 (11)
DOI 10.3390/cancers13112819, PubMed 34198773

Rognan SE, Kälvemark Sporrong S, Bengtsson K, Lie HB, Andersson Y, Mowé M, Mathiesen L (2021)
Discharge processes and medicines communication from the patient perspective: A qualitative study at an internal medicines ward in Norway
Health Expect, 24 (3), 892-904
DOI 10.1111/hex.13232, PubMed 33761170

Rognan SE, Kälvemark-Sporrong S, Bengtsson KR, Lie HB, Andersson Y, Mowé M, Mathiesen L (2021)
Empowering the patient? Medication communication during hospital discharge: a qualitative study at an internal medicines ward in Norway
BMJ Open, 11 (6), e044850
DOI 10.1136/bmjopen-2020-044850, PubMed 34193483

Svensberg K, Kalleberg BG, Mathiesen L, Andersson Y, Rognan SE, Sporrong SK (2021)
The observer effect in a hospital setting - Experiences from the observed and the observers
Res Social Adm Pharm, 17 (12), 2136-2144
DOI 10.1016/j.sapharm.2021.07.011, PubMed 34312101

Thorgersen EB, Asvall J, Frøysnes IS, Schjalm C, Larsen SG, Dueland S, Andersson Y, Fodstad Ø, Mollnes TE, Flatmark K (2021)
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol, 28 (9), 5252-5262
DOI 10.1245/s10434-021-10022-0, PubMed 34019185

Publications 2020

Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, Fodstad Ø, Andersson Y (2020)
Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma
Ann Diagn Pathol, 46, 151483
DOI 10.1016/j.anndiagpath.2020.151483, PubMed 32143173

Publications 2019

Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
Eur J Surg Oncol, 47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394

Johansen R, Andersson Y (2019)
Generic substitution of drugs in hospitals
Tidsskr Nor Laegeforen, 139 (1)
DOI 10.4045/tidsskr.17.0722, PubMed 30644679

Johansen R, Andersson Y (2019)
Generic change of medicines in hospitals
Tidsskr. Nor. Laegeforen., 139 (1), 36-40

Lode HE, Gjølberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, Jørstad ØK, Moe MC, Andersen JT (2019)
A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes
Sci Rep, 9 (1), 18021
DOI 10.1038/s41598-019-54226-7, PubMed 31792234

Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y (2019)
Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
Front Oncol, 9, 1302
DOI 10.3389/fonc.2019.01302, PubMed 31921617

Publications 2017

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
Pigment Cell Melanoma Res, 30 (5), 467-476
DOI 10.1111/pcmr.12599, PubMed 28513992

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367

Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, Asgari M (2017)
Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma
Exp Mol Pathol, 103 (2), 218-228
DOI 10.1016/j.yexmp.2017.10.001, PubMed 29050853

Zanjani LS, Madjd Z, Abolhasani M, Rasti A, Fodstad O, Andersson Y, Asgari M (2017)
Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma
Biomark Med, 12 (1), 45-61
DOI 10.2217/bmm-2017-0142, PubMed 29243496

Publications 2015

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Br J Cancer, 113 (11), 1548-55
DOI 10.1038/bjc.2015.380, PubMed 26554649

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
BMC Cancer, 15, 543
DOI 10.1186/s12885-015-1557-6, PubMed 26205955

Publications 2014

Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y (2014)
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
J Ovarian Res, 7, 23
DOI 10.1186/1757-2215-7-23, PubMed 24528603

Publications 2013

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Publications 2011

Risberg K, Fodstad Ø, Andersson Y (2011)
Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma
PLoS One, 6 (9), e24012
DOI 10.1371/journal.pone.0024012, PubMed 21915275

Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
J Immunother, 34 (5), 438-47
DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141

Publications 2010

Risberg K, Fodstad O, Andersson Y (2010)
Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells
J Immunother, 33 (3), 272-8
DOI 10.1097/CJI.0b013e3181c54991, PubMed 20445347

Risberg K, Fodstad O, Andersson Y (2010)
Immunotoxins: a promising treatment modality for metastatic melanoma?
Ochsner J, 10 (3), 193-9
PubMed 21603377

Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y (2010)
A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
Cancer Immunol Immunother, 59 (11), 1665-74
DOI 10.1007/s00262-010-0892-3, PubMed 20635083

Publications 2009

Risberg K, Fodstad Ø, Andersson Y (2009)
The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro
Int J Cancer, 125 (1), 23-33
DOI 10.1002/ijc.24317, PubMed 19350633

Publications 2006

Andersson Y, Le H, Juell S, Fodstad Ø (2006)
AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death
Mol Cancer Ther, 5 (4), 1050-9
DOI 10.1158/1535-7163.MCT-05-0318, PubMed 16648577

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
Anticancer Res, 26 (3A), 1909-16
PubMed 16827124

Publications 2005

Holthe MR, Andersson Y, Lyberg T (2005)
Lack of proinflammatory effects of free fatty acids on human umbilical cord vein endothelial cells and leukocytes
Acta Obstet Gynecol Scand, 84 (7), 672-8
DOI 10.1111/j.0001-6349.2005.00799.x, PubMed 15954878

Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
Mol Cancer Ther, 4 (8), 1231-8
DOI 10.1158/1535-7163.MCT-04-0304, PubMed 16093439

Publications 2004

Ahmed MS, Øie E, Vinge LE, Yndestad A, Øystein Andersen G, Andersson Y, Attramadal T, Attramadal H (2004)
Connective tissue growth factor--a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats
J Mol Cell Cardiol, 36 (3), 393-404
DOI 10.1016/j.yjmcc.2003.12.004, PubMed 15010278

Andersson Y, Juell S, Fodstad Ø (2004)
Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin
Int J Cancer, 112 (3), 475-83
DOI 10.1002/ijc.20371, PubMed 15382075

Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
Radiother Oncol, 72 (3), 305-10
DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729

Publications 2003

Ahmed MS, Øie E, Vinge LE, Yndestad A, Andersen G GØ, Andersson Y, Attramadal T, Attramadal H (2003)
Induction of myocardial biglycan in heart failure in rats--an extracellular matrix component targeted by AT(1) receptor antagonism
Cardiovasc Res, 60 (3), 557-68
DOI 10.1016/j.cardiores.2003.08.017, PubMed 14659801

Guren TK, Ødegård J, Abrahamsen H, Thoresen GH, Susa M, Andersson Y, Østby E, Christoffersen T (2003)
EGF receptor-mediated, c-Src-dependent, activation of Stat5b is downregulated in mitogenically responsive hepatocytes
J Cell Physiol, 196 (1), 113-23
DOI 10.1002/jcp.10282, PubMed 12767047

Publications 1999

Andersson Y, Majd Z, Lefebvre AM, Martin G, Sechkin AV, Kosykh V, Fruchart JC, Najib J, Staels B (1999)
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation
Arterioscler Thromb Vasc Biol, 19 (1), 115-21
DOI 10.1161/01.atv.19.1.115, PubMed 9888873

Publications 1997

Andersson Y, Lookene A, Shen Y, Nilsson S, Thelander L, Olivecrona G (1997)
Guinea pig apolipoprotein C-II: expression in E. coli, functional studies of recombinant wild-type and mutated variants, and distribution on plasma lipoproteins
J Lipid Res, 38 (10), 2111-24
PubMed 9374133

Publications 1996

Andersson Y, Nilsson S, Lindberg A, Thelander L, Olivecrona G (1996)
Apolipoprotein CII from chicken (Gallus domesticus). The amino-terminal domain is different from corresponding domains in mammals
J Biol Chem, 271 (51), 33060-6
DOI 10.1074/jbc.271.51.33060, PubMed 8955153

Publications 1991

Andersson Y, Thelander L, Bengtsson-Olivecrona G (1991)
Rat apolipoprotein C-II lacks the conserved site for proteolytic cleavage of the pro-form
J Lipid Res, 32 (11), 1805-9
PubMed 1770300

Andersson Y, Thelander L, Bengtsson-Olivecrona G (1991)
Demonstration of apolipoprotein CII in guinea pigs. Functional characteristics, cDNA sequence, and tissue expression
J Biol Chem, 266 (7), 4074-80
PubMed 1999402